Jazz Pharmaceuticals plc Credit Rating

Registrovaný uživatel

Abyste mohli plně využít Vaše oprávnění, musíte se přihlásit. Heslo rozlišuje malá a velká písmena.

Uživatelské jméno :

Heslo:

Automaticky mě přihlaste při návratu na stránky

Přihlásit se

Zapomněli jste své uživatelské jméno nebo heslo?

Nejste dosud registrováni?

Zaregistrujte se nyní a získáte VOLNÝ přístup na:

Ratingy emitentů.

Přes 170 000 ratingově sledovaných firemních, vládních a strukturovaných finančních cenných papírů.

Kalendář události.

Informace o výukových seminářích, brífincích a telekonferencích.

Watchlists.

Seznam emitentů sledovaných kvůli možnému přehodnocení ratingu.

Metodika ratingu.

Popis rámce pro zpracování ratingů udělovaných společností Moody's.

výsledků 1 - 37 Ze dne 37

Stránka 1 Ze dne 1 Next

Filtrovat dle:

Date	Typ dokumentu	Titre	Zdroj
15 Apr 2024	Issuer Profile	Jazz Pharmaceuticals plc: Key facts and statistics - 2023	Moody's Investors Service
31 Jan 2024	Credit Opinion	Jazz Pharmaceuticals plc: Update following upgrade of CFR to Ba2	Moody's Investors Service
25 Jan 2024	Rating Action	Moody's upgrades Jazz Pharma's CFR to Ba2; stable outlook	Moody's Investors Service
27 Jul 2023	Announcement of Periodic Review	Moody's announces completion of a periodic review for a group of Pharmaceutical issuers	Moody's Investors Service
23 Jan 2023	Credit Opinion	Jazz Pharmaceuticals plc: Update following outlook revision to positive	Moody's Investors Service
20 Jan 2023	LGD Assessment	Jazz Pharmaceuticals plc	Moody's Investors Service
20 Jan 2023	Rating Action	Moody's revises Jazz Pharma outlook to positive; affirms Ba3 CFR	Moody's Investors Service
04 Oct 2022	Announcement of Periodic Review	Moody's announces completion of a periodic review for a group of Pharmaceutical issuers	Moody's Investors Service
14 Jun 2022	LGD Assessment	Jazz Pharmaceuticals plc	Moody's Investors Service
11 Apr 2022	Credit Opinion	Jazz Pharmaceuticals plc: Update to credit analysis following outlook change to stable from negative	Moody's Investors Service
11 Apr 2022	Rating Action	Moody's affirms Jazz Pharma at Ba3; revises outlook to stable from negative	Moody's Investors Service
08 Nov 2021	Announcement of Periodic Review	Moody's announces completion of a periodic review of ratings of Jazz Pharmaceuticals plc	Moody's Investors Service
13 May 2021	Covenant Quality Assessment	Jazz Securities Designated Activity Company: Covenant Quality Post-Sale Snapshot: $1,500m 4.375% Senior Secured Notes due 2029	Moody's Investors Service
29 Apr 2021	LGD Assessment	Jazz Pharmaceuticals plc	Moody's Investors Service
12 Apr 2021	Credit Opinion	Jazz Pharmaceuticals plc: Update to credit analysis following GW acquisiton financing and negative outlook	Moody's Investors Service
09 Apr 2021	Rating Action	Moody's assigns Ba2 to Jazz Pharma's new secured credit facilities; negative outlook	Moody's Investors Service
24 Jul 2020	Credit Opinion	Jazz Securities Designated Activity Company: Update to credit analysis - Xywav and Zepzelca launches will help mitigate approaching Xyrem generics in 2023	Moody's Investors Service
09 Jun 2020	Announcement	Moody's: Jazz's new exchangeable notes issuance is credit negative	Moody's Investors Service
24 Jul 2019	Credit Opinion	Jazz Securities Designated Activity Company: Update to credit analysis - ongoing Sunosi launch will help mitigate 2023 Xyrem generic competition	Moody's Investors Service
15 Feb 2019	Announcement of Periodic Review	Moody's announces completion of a periodic review of ratings of Jazz Securities Designated Activity Company	Moody's Investors Service
30 Jul 2018	Credit Opinion	Jazz Securities Designated Activity Company: Update to credit analysis - Xyrem generic competition in 2023 will prompt acquisitions	Moody's Investors Service
22 May 2018	Rating Action	Moody's assigns Ba1 to Jazz Pharma's senior secured credit facilities	Moody's Investors Service
18 Aug 2017	Credit Opinion	Jazz Securities Limited: Update following refinancing of revolving credit facility with convertible notes and upgrade of secured debt rating	Moody's Investors Service
12 Apr 2017	Credit Opinion	Jazz Securities Limited: Update following outlook change to stable from negative	Moody's Investors Service
11 Apr 2017	Rating Action	Moody's affirms Jazz Pharma at Ba3; revises outlook to stable from negative	Moody's Investors Service
29 Jul 2016	Announcement	Moody's: Xyrem Patent Loss Is Credit Negative, but Other Patents Still Exist; Ratings Unaffected	Moody's Investors Service
29 Jul 2016	Issuer Comment	Jazz Securities Limited: Xyrem Patent Decision Is Credit Negative for Jazz, but Other Patents Still Valid; Ratings Unaffected	Moody's Investors Service
13 Jul 2016	Announcement	Moody's: Jazz's Upsized revolving credit facility is positive for liquidity; ratings unaffected	Moody's Investors Service
06 Jun 2016	Credit Opinion	Jazz Securities Limited: Update following announced acquisition of Celator Pharmaceuticals, Inc.	Moody's Investors Service
01 Jun 2016	Rating Action	Moody's affirms Jazz's Ba3 CFR; Outlook to Negative	Moody's Investors Service
01 Apr 2016	Announcement	Moody's: Approval of Jazz's Defitelio by the FDA is credit positive; ratings unaffected	Moody's Investors Service
19 Jun 2015	Rating Action	Moody's assigns Ba2 to Jazz's new senior secured bank facilities; stable outlook	Moody's Investors Service
07 Aug 2014	Rating Action	Moody's upgrades Jazz credit facilities to Ba2; affirms Ba3 CFR	Moody's Investors Service
09 Jan 2014	Rating Action	Moody's rates Jazz's senior secured debt Ba3; outlook stable	Moody's Investors Service
20 Dec 2013	Announcement	Moody's: Jazz pays high price for Gentium's modest EBITDA	Moody's Investors Service
30 May 2013	Announcement	Moody's: Jazz Pharma's upsized term loan is credit negative	Moody's Investors Service
15 May 2012	Rating Action	Moody's assigns Ba3 CFR to Jazz Pharmaceuticals; outlook stable	Moody's Investors Service

výsledků 1 - 37 Ze dne 37

Stránka 1 Ze dne 1 Next

Analýzy a Ratingy

Produkty a řešení

Novinky a události

Registrovaný uživatel

Nejste dosud registrováni?

Moody's Integrity Hotline

Via the Internet:

By telephone from the United States:

By telephone from outside the United States: